The average one-year price target for Elanco Animal Health (NYSE:ELAN) has been updated to $30.17 per share, reflecting a 10.94% increase from the previous estimate of $27.20 on February 21, 2026. This new target represents a 30.51% upside from the latest closing price of $23.12 per share, with analyst targets ranging from $24.24 to $33.60.
Currently, 494 funds report positions in Elanco, a decrease of 263 funds (34.74%) from last quarter. Institutional ownership has shrunk by 27.50%, with total shares held falling to 508,955K. The put/call ratio indicates a bullish sentiment at 0.53.
Key shareholders include Dodge & Cox with 79,084K shares (15.91% ownership), down 4.65%; Primecap Management with 46,214K shares (9.30% ownership), down 8.10% but with an increased portfolio allocation; and T. Rowe Price, which has reduced its holdings by 88.27% to 16,737K shares (3.37% ownership).
